European Journal of Heart Failure · 2024 · 10 citations · 16 references
PharmacyCardiologyPharmacoeconomicsCost-effectiveness AnalysisHealth Technology AssessmentPharmacoeconomic ModelingCost-effectiveness ComparisonCost-effectiveness ModelingHealth Care CostsHealthcare Cost AnalysisHeart FailureModel-based Economic EvaluationCost-effectivenessHealthcare Cost ImpactIncremental Cost EstimationLifetime HorizonMarkov Cost-effectiveness ModelsMedical Cost AnalysisQuality-adjusted Life Year PerspectiveStandard Of Care Comparators
AIMS: Remote haemodynamic monitoring with an implantable pulmonary artery (PA) sensor has been shown to reduce heart failure (HF) hospitalizations and improve quality of life. Cost-effectiveness analyses studying the value of remote haemodynamic monitoring in a European healthcare system with a contemporary standard care group are lacking. METHODS AND RESULTS: A Markov model was developed to estimate the cost-effectiveness of PA-guided therapy compared to the standard of care based upon patient-level data of the MONITOR-HF trial performed in the Netherlands in patients with chronic HF (New York Heart Association class III and at least one previous HF hospitalization). Cost-effectiveness was measured as the incremental cost per quality-adjusted life year (QALY) gained from the Dutch societal perspective with a lifetime horizon which encompasses a wide variety of costs including costs of hospitalizations, monitoring time, telephone contacts, laboratory assessments, and drug changes in both treatment groups. In the base-case analysis, PA-guided therapy increased costs compared to standard of care by €12 121. The QALYs per patient for PA-guided therapy and standard of care was 4.07 and 3.481, respectively, reflecting a gain of 0.58 QALYs. The resulting incremental cost-effectiveness ratio was €20 753 per QALY, which is below the Dutch willingness-to-pay threshold of €50 000 per QALY gained for HF. CONCLUSIONS: The current cost-effectiveness study suggests that remote haemodynamic monitoring with PA-guided therapy on top of standard care is likely to be cost-effective for patients with symptomatic moderate-to-severe HF in the Netherlands.
16
Dutch Tariff for the Five-Level Version of EQ-5D
Matthijs Versteegh, Karin M. Vermeulen, Silvia Evers et al. · Value in Health · 2016 · 1.1K citations · Full text
Update of the Dutch manual for costing studies in health care
Tim A. Kanters, Clazien Bouwmans, Naomi van der Linden et al. · PLoS ONE · 2017 · 276 citations · Full text
Christiane E. Angermann, Stefan D. Anker, Folkert W. Asselbergs et al. · European Journal of Heart Failure · 2020 · 214 citations · Full text